
NovoCure Limited
NASDAQ:NVCR
20.62 (USD) • At close March 12, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | NovoCure Limited |
Symbool | NVCR |
Munteenheid | USD |
Prijs | 20.62 |
Beurswaarde | 2,266,447,300 |
Dividendpercentage | 0% |
52-weken bereik | 11.7 - 34.13 |
Industrie | Medical Instruments & Supplies |
Sector | Healthcare |
CEO | Mr. Asaf Danziger |
Website | https://www.novocure.com |
An error occurred while fetching data.
Over NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)